Vamsidhar Velcheti, MD
Hematology & Oncology · Jacksonville, FLNPI 1477744316
Payments from drug & device makers
Across 1,192 payments — averaging $6848.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.2M
- Amgen$1.3M
- GSK$1.3M
- E.r. Squibb & Sons, L.L.C.$836K
- Helsinn Healthcare SA$552K
- Genentech, Inc.$482K
- plus $1.6M from 38 others
Across 8 payments — averaging $1259.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
- Amgen$3K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$361,66937%
- Speaking & faculty fees$119,21812%
- Grants$380,00039%
- Travel & lodging$92,91210%
- Food & beverage$10,3171%
- Education$1,4350%
- Charitable contribution$5690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$68,775
- FOUNDATIONONE LIQUID$50,525
- FOUNDATIONFOCUS$50,525
- FOUNDATIONONE HEME$50,525
- FOUNDATIONONE$50,525
- LYNPARZA$47,900
- KEYTRUDA$37,507
- TAGRISSO$20,998
- LIBTAYO$16,763
- LUMAKRAS$14,028
- IMFINZI$13,572
- Ibrutinib$13,194
- Lenalidomide$13,194
- Abiraterone$13,194
- RYBREVANT$12,794
- TECENTRIQ$8,818
- ALUNBRIG$5,771
- Oncology$5,324
- OPDIVO$4,675
- ICEFX$3,933
How this compares
$8,162,927 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Jacksonville
- Steven AttiaJacksonville$13.9M
- Sikander AilawadhiJacksonville$9.8M
- Asher Chanan KhanJacksonville$5.8M
- Yanyan LouJacksonville$4.8M
- Arnab BasuJacksonville$4.6M
- James ForanJacksonville$4.6M
- Jennifer CrozierJacksonville$3.5M
- Ayed AyedJacksonville$3.4M
- Saranya ChumsriJacksonville$3.3M
- Gerardo Colon-OteroJacksonville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.